Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen (phenylephrine HCl) Co-Promotion Agreement - Xellia's U.S.- Based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with Eto

Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen (phenylephrine HCl) Co-Promotion Agreement

PARK, Ill., Jan. 21, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company

focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with

Xellia Pharmaceuticals for the promotion of Biorphen (phenylephrine HCl), the first and only FDA approved ready-to-use

formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from

vasodilation in the setting of anesthesia.

are excited to collaborate with Xellia on the promotion of Biorphen. Given our overlapping target markets, this agreement is a

compelling opportunity for Eton to increase Biorphen's commercial footprint and leverage Xellia's established relationships

with hospitals that have adopted ready-to-use injectable products," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "We

have been pleased with the customer reaction to Biorphen in our first few weeks since launch, and we look forward to working with

Xellia to continue driving adoption of Biorphen"

is a great opportunity for us to work with Eton to co-promote Biorphen; the collaboration fits well with our overall mission to

bring life-saving medicines that address unmet patients' needs. Eton has a similarly bold company culture and focus to Xellia,

which aligns with our ambition to bring more ready-to-use products to the US market where time is critical to the patient and

in alignment to industry guidelines" said Carl-Aake Carlsson, CEO of Xellia Pharmaceuticals.

hospital sales force will immediately begin promoting Biorphen in certain market segments in collaboration with Eton's existing

commercial team. The agreement significantly increases the number of sales representatives actively promoting Biorphen and provides

Eton with immediate access to accounts that have already adopted Xellia's Vanco Ready, a ready-to-use formulation of Vancomycin

injection. In addition, Xellia will be expanding its sales force to support the co-promotion. Eton will continue to promote Biorphen

to all market segments. Xellia will receive a commission on Biorphen sales realized from certain customer accounts.

(phenylephrine HCI) Injection is the first and only FDA-approved ready-to-use formulation of phenylephrine for treating

clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Ready-to-use Biorphen can

be standardized and stocked in operating rooms, emergency departments and intensive care units, as well as in crash carts throughout

the hospital. With a three-year shelf life, Biorphen can be stocked throughout hospitals without frequent restocking. The market

for ready-to-use phenylephrine injection is estimated to be more than 20 million doses annually.

injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting

primarily from vasodilation in the setting of anesthesia.

and Precautions: BIORPHEN can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate

underlying heart failure, and increase pulmonary arterial pressure. Can also cause excessive peripheral and visceral vasoconstriction

and ischemia to vital organs. Extravasation during intravenous administration may cause necrosis or sloughing of tissue. Can cause

severe bradycardia and decreased cardiac output, renal toxicity, augmented pressor effect in patients with autonomic dysfunction

and pressor effect with concomitant oxytocic drugs.

common adverse reactions during treatment: nausea, vomiting, and headache.

report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals, Inc. at 1-888-450-0568 or FDA at 1-800-FDA-1088.

Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic

drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot

Effects (decrease in BIORPHEN blood pressure effect) can occur with -adrenergic antagonists, phosphodiesterase Type 5 inhibitors,

mixed - and -receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting

sympatholytic agents

of BIORPHEN (phenylephrine hydrochloride) can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting,

hypertension, reflex bradycardia, a sensation of fullness in the head, tingling of the extremities, and cardiac arrhythmias including

ventricular extrasystoles and ventricular tachycardia.

Eton Pharmaceuticals, Inc.

Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing

the FDA's 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids

and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic

areas, including multiple product candidates currently under review by the FDA.

Xellia Pharmaceuticals

Pharmaceuticals ("Xellia") is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective

treatments against serious and often life-threatening bacterial and fungal infections.

over 100 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs,

comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company's evolution, Xellia

is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience

and ease of use for healthcare professionals.

in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia

and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States.

Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,700 people.

contained in this press release regarding matters that are not historical facts are "forward-looking statements" within

the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability

of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited

to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates,

the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory

filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements

are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking

statements. Words such as "believes," "anticipates," "plans," "expects," "intends,"

"will," "goal," "potential" and similar expressions are intended to identify forward-looking

statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may

never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated

in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated

with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics,

and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs

and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission.

All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes

no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they